Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Abstract
Purpose: Telomerase promoter mutations are highly prevalent in human tumors including melanoma. A subset of patients with metastatic melanoma often fail multiple therapies, and there is an unmet and urgent need to prolong disease control for those patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2018
- Source ID
- 10.1158/1078-0432.ccr-17-2773
Entities
People
- Aurelie Beroard
- Benchun Miao
- Bradley Garman
- Bradley Wubbenhorst
- Chaoran Cheng
- Clemens Krepler
- Dennie T. Frederick
- Eric Sugarman
- Gao Zhang
- Genevieve M. Boland
- Giorgos C. Karakousis
- Gordon B. Mills
- Ilgen Mender
- Jerry W. Shay
- Jiufeng Tan
- Jonathan Woo
- Katherine L Nathanson
- Katrin Sproesser
- Keith T. Flaherty
- Lawrence N. Kwong
- Lawrence W. Wu
- Lynn M. Schuchter
- Marc R. Hammond
- Meenhard Herlyn
- Michal Barzily-rokni
- Min Xiao
- Norah Sadek
- Omotayo Ope
- Patricia Brafford
- Qin Liu
- Rajasekharan Somasundaram
- Ravi K. Amaravadi
- Sengottuvelan Murugan
- Sergio Randell
- Tara C. Mitchell
- Themistoklis Vasilopoulos
- Tian Tian
- Umar Saeed
- Utz Herbig
- Wei Xu
- Wei Zhi
- Xiangfan Yin
- Xiaowei Xu
- Yiling Lu
Organizations
- Adelson Foundation
- Hospital of the University of Pennsylvania
- King Abdulaziz University
- Massachusetts General Hospital
- National Cancer Institute
- New Jersey Institute of Technology
- Rutgers University
- United States Department of Defense
- University of Pennsylvania
- University of Texas Southwestern Medical Center
- University of Texas at Austin
- Wistar Institute